Dr Reddy’s Laboratories launches COVID-19 treatment drug in India

By: |
Updated: Aug 21, 2020 4:08 PM

"The launch is part of the global licensing agreement with Fujifilm Toyama Chemical Co Ltd that grants Dr Reddy's the exclusive rights to manufacture, sell and distribute Avigan (Favipiravir) 200 mg tablets in India," the drug major said in a regulatory filing.

Shares of Dr Reddy’s Laboratories were trading 0.10 per cent higher at Rs 4508.90 apiece on the BSE.

Dr Reddy’s Laboratories on Wednesday announced the launch of Avigan (Favipiravir) tablets, used for treating mild to moderate COVID-19 , in India.

“The launch is part of the global licensing agreement with Fujifilm Toyama Chemical Co Ltd that grants Dr Reddy’s the exclusive rights to manufacture, sell and distribute Avigan (Favipiravir) 200 mg tablets in India,” the drug major said in a regulatory filing.

Dr Reddy’s said Avigan has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19.

“The need for high quality and efficacy, affordability and better disease management are key priorities for us. We believe that Avigan would provide an effective treatment option to the COVID-19 impacted patients in India,”M V Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories, said.

Shares of Dr Reddy’s Laboratories were trading 0.10 per cent higher at Rs 4508.90 apiece on the BSE.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid-19: Pune hospitals struggle with critical patients; doctors, hospital staff crunch likely
2Covid-19 vaccine update: Phase 3 human clinical trial of Oxford vaccine begins in Pune
3India needs to invest Rs 3,000-5,000 crore to create extra manufacturing facilities for COVID-19 vaccine: Zydus Cadila chairman